Wolverine Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Wolverine Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-110	Closed	-$61K	–	2281
2021 Q2	$61K	Sell	110 -166	-60%	-$84.1K	﹤0.01%	1613
2021 Q1	$130K	Buy	276 +202	+273%	+$98.3K	﹤0.01%	1374
2020 Q4	$35K	Sell	74 -127	-63%	-$68.6K	﹤0.01%	1383
2020 Q3	$112K	Buy	201 +196	+3,920%	+$119K	﹤0.01%	1115
2020 Q2	$3K	Buy	+5	New	+$2.84K	﹤0.01%	1461
2017 Q1	–	Sell	-100	Closed	-$36K	–	1354
2016 Q4	$36K	Hold	100	–	–	﹤0.01%	1045
2016 Q3	$40K	Hold	100	–	–	﹤0.01%	1077
2016 Q2	$34K	Hold	100	–	–	﹤0.01%	1062
2016 Q1	$36K	Buy	+100	New	+$41.2K	﹤0.01%	919
2015 Q3	–	Sell	-46,309	Closed	-$24.9M	–	1954
2015 Q2	$23.6M	Buy	+46,309	New	+$22.6M	0.54%	41

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Wolverine Asset Management's REGN Position: Q3 2021 in Review

Wolverine Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2021, closing a stake of 110 shares — an estimated $61K sold.

Wolverine Asset Management first reported a position in REGN in Q2 2015 and held it in 10 quarters. The position peaked at $23.6M in Q2 2015. 1,019 funds tracked by Wall St. Rank hold REGN as of Q3 2021.

Wolverine Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Wolverine Asset Management sold 110 Regeneron Pharmaceuticals shares in Q3 2021, an estimated $61K.
Wolverine Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 10 quarters.
Wolverine Asset Management's Regeneron Pharmaceuticals position peaked at $23.6M in Q2 2015.
1,019 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2021.

Based on Wolverine Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.